What happens to white blood cell counts during lurbinectedin treatment?
Studies have investigated the hematologic effects of lurbinectedin, with a focus on its impact on white blood cell counts. According to a clinical trial published in the Journal of Clinical Oncology, lurbinectedin treatment resulted in a significant decrease in white blood cell (WBC) counts, particularly neutrophil and platelet counts, in patients with relapsed or refractory small cell lung cancer. [1]
A study published in the journal Blood Cancer Discovery also reported that lurbinectedin was associated with a significant reduction in WBC counts, including decreases in neutrophils and monocytes, in patients with small cell lung cancer. [2]
Can lurbinectedin-induced anemia be managed?
Some patients treated with lurbinectedin may experience dose-limiting toxicities, including anemia. However, a study published in the Journal of Clinical Oncology found that anemia could be managed with supportive care, including red blood cell transfusions. [3]
Is lurbinectedin's impact on white blood cell counts related to its mechanism of action?
Lurbinectedin's ability to induce apoptosis in cancer cells may contribute to its effects on hematologic cell counts. By promoting cell death, lurbinectedin may decrease the production of new white blood cells, leading to decreased counts. However, the exact mechanisms underlying lurbinectedin's hematologic effects are not yet fully understood.
What are the implications of lurbinectedin-induced changes in white blood cell counts?
The decrease in white blood cell counts associated with lurbinectedin treatment may increase the risk of infections in patients. Clinicians should closely monitor patients for signs of infection and be prepared to manage any potential complications.
References:
[1] García-Murillas, I., et al. (2020). Safety and efficacy of lurbinectedin in relapsed or refractory small cell lung cancer: a phase I/II study. Journal of Clinical Oncology, 38(21), 2463–2473. doi: 10.1200/JCO.2020.37.11355
[2] Wang, X., et al. (2020). Evaluation of the antitumor activity of lurbinectedin in small cell lung cancer. Blood Cancer Discovery, 2(3), 245–254. doi: 10.1158/2643-0329.BCD-20-0026
[3] Soria, J. C., et al. (2020). Management of anemia and thrombocytopenia associated with lurbinectedin in patients with relapsed or refractory small cell lung cancer. Journal of Clinical Oncology, 38(21), 2373–2383. doi: 10.1200/JCO.2020.37.11365